{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T16:26:03Z","timestamp":1775147163851,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00277-022-04912-w","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T10:15:01Z","timestamp":1662372901000},"page":"2525-2528","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Venetoclax combined with decitabine and HAAG regimen: a novel salvage strategy for relapsed\/refractory T-cell acute lymphoblastic leukaemia"],"prefix":"10.1007","volume":"101","author":[{"given":"Yuanxin","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"key":"4912_CR1","unstructured":"Swerdlow SH, Campo E, Harris NL, et al. 2008 WHO classification of tumours of haematopoietic and lymphoid tissues. Vol 4t"},{"issue":"4","key":"4912_CR2","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s11684-012-0224-4","volume":"6","author":"M Ma","year":"2012","unstructured":"Ma M, Wang X, Tang J et al (2012) Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia. Front Med 6(4):416\u2013420","journal-title":"Front Med"},{"issue":"9","key":"4912_CR3","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.leukres.2013.06.010","volume":"37","author":"A Allen","year":"2013","unstructured":"Allen A, Sireci A, Colovai A et al (2013) Early T-cell precursor leukemia\/lymphoma in adults and children. Leuk Res 37(9):1027\u20131034","journal-title":"Leuk Res"},{"key":"4912_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1532\/IJH97.A10424","volume":"82","author":"JM Li","year":"2005","unstructured":"Li JM, Shen Y, Wu DP et al (2005) Aclarubicin and low-dose cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients. Int J Hematol 82:45\u201354","journal-title":"Int J Hematol"},{"issue":"8","key":"4912_CR5","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.18632\/oncotarget.3361","volume":"6","author":"JY Li","year":"2015","unstructured":"Li JY, Chen YY, Zhu Y et al (2015) Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia. Oncotarget 6(8):6448\u20136458","journal-title":"Oncotarget"},{"issue":"21","key":"4912_CR6","first-page":"00739","volume":"S2666\u20136367","author":"SN Liu","year":"2021","unstructured":"Liu SN, Cui QY, Dai HP et al (2021 Feb 28) Early T-cell precursor acute lymphoblastic leukemia and T\/myeloid mixed phenotype acute leukemia possess overlapping characteristics and both benefit from CAG-like regimens and allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther S2666\u20136367(21):00739\u201300749","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"4912_CR7","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","volume":"20","author":"R Guillaume","year":"2020","unstructured":"Guillaume R, Elias J, Nicholas J et al (2020) Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 20(4):212\u2013218","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"4912_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00277-019-03902-9","volume":"99","author":"X Zhang","year":"2020","unstructured":"Zhang X, Li JH, Jin J et al (2020 Feb) Relapsed\/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen. Ann Hematol 99(2):395\u2013397","journal-title":"Ann Hematol"},{"key":"4912_CR9","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00277-020-03911-z","volume":"99","author":"YW Wang","year":"2020","unstructured":"Wang YW, Tsai CH, Lin CC et al (2020) Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. Ann Hematol 99:501\u2013511","journal-title":"Ann Hematol"},{"issue":"3","key":"4912_CR10","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/cam4.2757","volume":"9","author":"A Sakhdari","year":"2020","unstructured":"Sakhdari A, Thakral B, Loghavi S et al (2020 Feb) RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD. Cancer Med 9(3):849\u2013858","journal-title":"Cancer Med"},{"key":"4912_CR11","doi-asserted-by":"crossref","unstructured":"Kong JY, Chen N, Li\u00a0M, et al. 2021 Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia. Ann Hematol, May 6","DOI":"10.1007\/s00277-021-04530-y"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04912-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04912-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04912-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T05:05:40Z","timestamp":1665119140000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04912-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":11,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["4912"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04912-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,5]]},"assertion":[{"value":"23 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Yuanxin Zhu declares that he has no conflict of interest. Yin Dai declares that she has no conflict of interest. Xiaowen Tang declares that she has no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}